Physician profile
Lawrence D Brenner
NPI 1225010317
$15,496.92
in general payments reported to CMS, 2019-2025
34 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,105 · 2020: $2,220 · 2021: $3,348 · 2022: $3,093 · 2023: $2,590 · 2024: $887 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,731.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,476.36 | 2021-2025 | Micra, Corevalve Evolut R, Onyx Frontier |
| Abiomed | $3,399.20 | 2019-2024 | Impella |
| Medtronic Vascular, INC. | $2,113.70 | 2019-2020 | |
| Abbott Laboratories | $900.76 | 2020-2023 | Cardiomems, Pressurewire |
| Janssen Pharmaceuticals, INC | $484.63 | 2019-2023 | Xarelto |
| Biotronik INC. | $316.94 | 2022-2023 | Orsiro Mission |
| Merck Sharp & Dohme LLC | $292.40 | 2021-2023 | Verquvo |
| Esperion Therapeutics, INC. | $228.62 | 2020-2023 | Nexletol |
| W. L. Gore & Associates, INC. | $223.52 | 2021-2022 | |
| Biosense Webster, INC. | $216.11 | 2021 | |
| Bard Peripheral Vascular, INC. | $203.63 | 2020 | |
| Ekos Corporation | $151.95 | 2019 | |
| Shockwave Medical, INC | $144.28 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cardiovascular Systems INC. | $143.98 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $141.15 | 2024 | Optimizer |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $133.62 | 2021-2023 | |
| Philips North America LLC | $113.68 | 2022 | |
| Cvrx, INC. | $107.61 | 2024 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $101.43 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $76.73 | 2019-2021 | |
| Pfizer INC. | $71.10 | 2019-2022 | |
| Celonova Biosciences, INC. | $67.40 | 2019 | |
| Alnylam Pharmaceuticals INC. | $56.43 | 2023 | Onpattro |
| Amgen INC. | $55.67 | 2020-2022 | |
| Getinge USA Sales, LLC | $52.96 | 2019 | |
| Silk Road Medical, INC. | $45.04 | 2022 | |
| Amarin Pharma, INC. | $45.00 | 2020-2021 | |
| Acist Medical Systems, INC. | $28.00 | 2021 | |
| Angiodynamics, INC. | $20.85 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.83 | 2021 | |
| Boston Scientific Corporation | $19.92 | 2020 | |
| Heartflow, INC. | $17.20 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.34 | 2022 | |
| Chiesi USA, INC. | $12.88 | 2023 | Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Brenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.